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ABSTRACT 
The presence of ageing-associated disorders at a relatively young age in patients suffering 
from chronic kidney disease (CKD) has led to the hypothesis that CKD is characterized by 
accelerated ageing, resulting in a marked discrepancy between chronological and biological 
age. Factors that accelerate biological ageing, such as inflammation, oxidative stress, and 
toxins, impact the processes of cellular senescence and/or apoptosis, thereby shortening 
the life span of cells, and consequently, of the organism as a whole. 
Numerous studies have linked increased cellular senescence and apoptosis to disorders 
commonly associated with ageing, such as cardiovascular disease (CVD), osteoporosis, and 
cognitive dysfunction – all of which are common in the uremic phenotype. 
In Study I, we demonstrate that increased arterial gene expression of cyclin-dependent 
kinase inhibitor 2A (CDKN2A), a known inducer of cellular senescence, is associated with the 
presence of CVD and vascular calcification (VC) in CKD patients. Furthermore, there is a 
positive correlation between CDKN2A expression and the expression of matrix Gla protein 
(MGP) and runt-related transcription factor 2 (RUNX2), both of which are involved in 
osteogenesis. We also show a tentative relationship between a higher degree of VC and 
increasing p16INK4a expression, a cognate protein of CDKN2A. 
In Study II, we use telomere length as a biomarker of biological age, showing that CKD 
patients have shorter telomeres than non-CKD controls. In addition, our results indicate a 
possible association between longitudinal telomere length, folate, and immunosuppressive 
treatment in patients undergoing renal transplantation (RTx). This suggests that anti-
metabolite therapy may have an impact on biological ageing in RTx patients. 
In Study III, we show that the global methylation status in dialysis and RTx patients at 
baseline and after 12 months of renal replacement therapy (RRT) differs at several sites in 
the genome from that of age- and gender-matched healthy controls. Furthermore, 
differences in methylation between patients and controls can be found at CpG sites located 
in genes with known functional relevance to CKD, cellular ageing, CVD and/or metabolic 
disease. 
Continuing our investigations of factors affecting epigenetic status, Study IV investigates the 
association between the degree of self-reported physical activity and global DNA 
methylation in Swedish seniors. In this study, we demonstrate that individuals who reported 
higher physical activity had less global DNA methylation than those who were less physically 
active.  
Study V describes the application of a multifactorial mathematical model for predicting the 
presence of inflammation in a dataset generated from 225 incident dialysis patients. Eight of 
the ten features with the highest predictive factor were single nucleotide polymorphisms 
(SNPs), suggesting a large genetic influence on inflammation in CKD patients. 
In Study VI, the interplay between inflammatory status, genotype, and mortality is 
demonstrated in two cohorts of incident dialysis patients. The mortality was reduced in 
inflamed individuals carrying a 32 base-pair deletion in the C-C motif chemokine receptor 5 
(CCR5) gene compared to individuals who were inflamed but lacked the deletion. 
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1 INTRODUCTION 
1.1 CHRONIC KIDNEY DISEASE 
Chronic kidney disease (CKD) encompasses a variety of aetiologies with the common 
denominator of a progressive degradation of kidney function. It is divided into different 
stages according to glomerular filtration rate (GFR), where lower GFR reflects a more severe 
stage of the disease. The different stages are presented below in Table 1. The most severe 
stage of CKD, stage 5, is termed end-stage renal disease (ESRD), which occurs when the GFR 
is below 15 mL/min/1.73 m2 1. At this stage, the patient requires renal replacement therapy 
(RRT) in the form of dialysis or renal transplantation (RTx) to survive. 
 
CKD stage GFR (mL/min/1.73 m2) Description 
1 ≥90 Normal renal function with abnormal urine 
findings or genetic predisposition to CKD 
2 60-89 Mild reduction in renal function with abnormal 
urine findings or genetic predisposition to CKD 
3a 45-59 Moderate reduction in renal function 
3b 30-44 Moderate reduction in renal function 
4 15-29 Severe reduction in renal function 
5 <15 Very severe reduction in renal function 
Table 1. Stages of chronic kidney disease2. 
1.1.1 Incidence and prevalence 
The prevalence of CKD is growing worldwide, and has become a global health problem3, 4. 
About 10-12% of the population is currently estimated to suffer from CKD in Western 
countries4, 5, and in 2010, 2.62 million people worldwide received RRT6. Consequently, the 
societal cost for CKD treatment – in terms of medical costs and patient disability – is 
increasing rapidly3, 5. 
Chronic kidney disease is a complex disease, with a number of contributing factors, some of 
which are known while others are as yet unknown. These factors may be genetic7, 8 or 
environmental9, and lead not only to the development of CKD but also to its devastating 
comorbidities and complications. 
1.1.2 Treatments 
The two main kinds of RRT available are dialysis and RTx. Dialysis treatment can be divided 
into haemodialysis (HD) and peritoneal dialysis (PD). In the case of RTx, patients commonly 
receive additional medication, such as immunosuppressants. 
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1.1.2.1 Immunosuppressive (antimetabolite) therapy 
Patients receiving a renal transplant are routinely on immunosuppressive medication with 
the purpose of preventing organ rejection. Study II focuses on the particular 
immunosuppressive medications azathioprine (Imurel®) and mycophenolic acid mofetil 
(CellCept®), both of which are antimetabolite drugs. These drugs inhibit two different 
enzymes in the purine synthesis pathway – amidophosphoribosyltransferase (azathioprine) 
and inosine monophosphate dehydrogenase (mycophenolic acid)10-12 – which reduces cell 
proliferation, particularly in lymphocytes12.  
1.1.3 Comorbidities and their risk factors 
The healthcare costs and the strain on CKD patients are not solely due to RRT. Patients 
suffering from CKD are prone to a long list of different comorbidities – cardiovascular 
disease (CVD)13-15, osteoporosis16, cognitive dysfunction16, frailty, protein energy wasting 
(PEW)17, and sarcopenia16, to name a few – all  occurring at a much higher rate than in 
healthy subjects of the same age, indicating a substantial discrepancy between 
chronological and biological age16, 18, 19. 
The reason(s) why CKD patients exhibit such a markedly increased risk of age-associated 
diseases is largely unknown. Biologically relevant hypotheses include the presence of 
chronic low-grade inflammation20, hypogonadism, increased oxidative stress21, elevated 
systemic levels of uremic toxins22, and, possibly, the effects of medications23. These 
processes have all been associated with increased cellular senescence, giving rise to an 
accelerated biological ageing process. 
1.1.3.1 Inflammation 
An often observed phenomenon in CKD, and indeed in many other chronic diseases, is the 
presence of inflammation. Inflammation is often defined as an elevated (> 5 mg/L) systemic 
level of C-reactive protein (CRP), which is readily measured in blood24. There are numerous 
other pro-inflammatory markers with functional roles in propagating inflammatory 
processes. Chief among these is interleukin-6 (IL-6), a universally expressed pro-
inflammatory cytokine which has been suggested to be a more specific indicator of 
inflammation, PEW, and CVD risk than CRP25, 26. The release of CRP and IL-6 can be induced 
by IL-1β, a pro-inflammatory cytokine which requires an inflammasome to become active27. 
The best studied inflammasome, NLR family pyrin domain containing 3 (NLRP3), can be 
activated by uric acid, among other factors27. Interleukin-6 is also a major component of the 
senescence-associated secretory phenotype (SASP), which is defined by the secretion of a 
set of molecules by senescent cells (see below).  
Inflammation has long been considered an aggravating, or potentially causative, factor in 
the development of CVD28, 29. Not surprisingly, the presence of inflammation has also been 
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linked to an increased risk of overall and cardiovascular mortality30-32. There are several 
studies showing that inflammatory processes are associated with both intimal and medial 
vascular calcification (VC), as reviewed by Amann33. Proinflammatory cytokines facilitate the 
osteogenic transformation of vascular smooth muscle cells (VSMCs), either by direct action 
or indirectly through an increased level of oxidative stress33 .  
While part of the immune response is dependent on environmental components, the 
inflammatory process is also dictated by genetic factors, which contribute to the inter-
individual differences observed in response to challenges to the immune system. An 
example of a genetic factor that affects infection and inflammation is the C-C motif 
chemokine receptor 5 (CCR5) gene, where a deletion of 32 base pairs (CCR5Δ32) renders the 
resulting CCR5 protein non-functional34. The CCR5 protein is expressed on the surface of T 
cells and macrophages, and is, among other things, involved in recruiting inflammatory cells 
to the endothelium following the binding of its ligands C-C motif chemokine ligand 3 (CCL-3), 
CCL-4, and CCL-535. It also functions as a co-receptor for the human immunodeficiency virus-
1 (HIV-1)36, 37. With a minor allele frequency of about 10% in populations of European 
descent34, 38, the CCR5Δ32 variant is associated with restriction of HIV-1 infection as well as 
slower progression to AIDS in HIV-1-infected individuals34. In addition, CCR5 and its ligands 
have been implied in the atherosclerotic process39-42, and the CCR5Δ32 variant is associated 
with an improved prognosis in patients with atherosclerosis43-47. 
Exercise has been shown to reduce the level of high-sensitivity CRP (hsCRP), both in healthy 
individuals and in patients with heart disease48. While the exact pathways are not yet 
defined, exercise appears to affect the expression of several inflammation-related genes in 
immune cells, such as toll-like receptor (TLR) genes, NF-κB, nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidases, and superoxide dismutases (SODs)49. In addition, 
exercise is considered to be a first line treatment for patients diagnosed with type 2 
diabetes mellitus (T2DM), as it has been shown to improve markers of metabolic disease50. 
There is also a link between exercise and CKD, as Viana et al. found that aerobic exercise 
might serve as anti-inflammatory therapy in CKD patients51. Overall, exercise and physical 
activity have been proposed to reduce ageing-related disorders, such as CVD, diabetes 
mellitus (DM), Alzheimer’s disease, osteoporosis, and cancer52. Considering the 
pathophysiology of CKD, CVD, DM and inflammation, such interconnections are perhaps not 
surprising. 
1.1.3.2 Vascular calcification and cardiovascular disease 
The most prominent comorbidity seen in CKD patients is CVD. Concomitant with a decrease 
in renal function, there is an exponential increase in total and cardiovascular mortality14, 53. 
The incidence and prevalence of CVD – and CVD mortality – is markedly increased in CKD 
patients compared to age-matched individuals in the general population13, 15. There are 
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numerous forms of CVD, which is a complex disease in its own right. In the context of CKD, 
several CVD risk factors are present and have also been suggested to be involved in the 
pathogenesis of CVD in this patient group. For instance, the sustained presence of uremic 
toxins in CKD patients contributes to an increased CVD risk54, partly through an elevated 
degree of oxidative stress55, 56. 
A major CVD risk factor is arterial stiffening and/or vascular calcification, a process which is 
termed arteriosclerosis. Atherosclerosis, a form of vascular disease, refers to the deposition 
of lipid particles in the intima of the arterial wall, resulting in the formation of fatty streaks 
and plaques that restrict the lumen and hence the blood flow. There are two different forms 
of VC, named after their site of occurrence – intimal or medial calcification. Vascular medial 
calcification is a major risk factor for developing CVD, and predicts cardiovascular morbidity 
and mortality in HD patients57. The process of VC in CKD is characterised by the phenotypic 
transformation of VSMCs in the arterial wall, resulting in stiffening and an increased risk of 
CVD, such as cardiac failure and stroke22, 58. Medial calcification, or Mönckeberg’s sclerosis, 
is traditionally viewed as an age-related process, as it is commonly observed in elderly 
individuals58. Although rare in the general population, medial calcification is prevalent in 
chronic diseases such as CKD59, DM59, osteoporosis60, systemic lupus erythematosus33, 
certain genetic disorders33, and rare progeroid diseases22. In fact, medial and intimal 
calcification appear to be two distinct processes in CKD, and each has its own clinical 
symptoms and consequences33, 58. Intimal calcification is related to atherosclerosis and the 
presence of a prominent inflammatory component in the form of macrophages60, while 
medial calcification (arteriosclerosis) apparently lacks lipid deposits and is more closely 
associated with osteogenic transformation of VSMCs33, 60.  
Osteogenic transformation of VSMCs appears to be central to the VC process54. When 
exposed to a stressor such as high phosphate, VSMCs have the potential to re-differentiate 
into an osteoblast-like phenotype, which stimulates and supports the calcification process in 
the vessel wall54. This transition is aided by factors such as runt-related transcription factor 2 
(RUNX2)61, 62, while inhibitory factors such as matrix Gla protein (MGP), which attempt to 
reduce the amount of extracellular calcification, are typically down-regulated63, 64. While 
overall expression of MGP is low in Mönckeberg’s sclerosis, it is expressed at high levels in 
VSMCs from calcified regions65. 
1.2 AGEING 
The concept of age traditionally refers to the number of days, months or years that have 
passed since an individual was born, also known as chronological age. Biological age is 
another form of age, which does not necessarily equal the chronological age of a person, 
but rather refers to the physical age of the entire organism – organs, tissues etc. – and is in 
essence a reflection of the cellular age.  
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Cells age more or less rapidly depending on their surroundings, a process which is termed 
senescence. If they age quickly, the biological age exceeds the chronological age, and vice 
versa. Increased senescence is hypothesised to result in organ and tissue dysfunction, which 
ultimately leads to disease conditions associated with premature ageing23, 66. Whereas 
cellular senescence accumulates during normal ageing, there are diseases and 
environmental factors that accelerate the ageing process, such as smoking, chemotherapy, 
and kidney transplantation23. Immunosuppressive treatment may further add to biological 
ageing, as it reduces the clearance of senescent cells23. 
1.2.1 Senescence 
In order to protect the organism from unrestricted cellular replication, i.e. cancer, a number 
of intrinsic mechanisms are designed to terminate, or make latent, a particular cell after it 
has reached a critical number of cell divisions. These processes are vital not only to prohibit 
cancer, but also for the formation of tissues and organs, especially during foetal 
development and wound healing67-69. In addition, senescent cells accumulate in tissues 
during normal ageing, and are believed to directly contribute to the ageing phenotype23. 
The word senescence is derived from Latin and means “to grow old”. It is the process 
whereby old cells cease to replicate and become latent or dormant. A schematic overview of 
triggers of senescence is shown in Figure 1. While the cells no longer divide, they retain 
many of their functional characteristics and are fully capable of secreting various factors, 
thereby affecting nearby cells and tissues23, 66, 70. In fact, senescent cells have been likened 
to carcinogenic cells, in that they both exhibit an increased resistance to apoptosis71-73. 
Furthermore, senescent cells are potentially harmful as they may acquire a SASP, which 
involves the secretion of a panel of factors mainly consisting of growth factors, pro-
inflammatory cytokines, metalloproteinases, and chemoattractants74, 75. The exact 
composition of the SASP varies slightly depending on cell type and/or stressor – however, it 
is consistently pro-inflammatory in nature23, 74. Due to the SASP, senescent cells have been 
proposed to be involved in causing, or aggravating, many chronic diseases characterised by 
low-grade inflammation, such as DM, Alzheimer’s disease, osteoarthritis, and cancer23, 70. As 
reviewed by Burton et al.76, IL-6 – a prominent SASP component – appears to promote 
osteoblast transformation, thereby further linking senescence, (local) inflammation, and VC. 
Because of the SASP, senescent cells are able to affect tissue and organ function 
disproportionately to their numbers. 
Senescence of VSMCs has been repeatedly linked to VC65, 76, 77. In a study by Buendía et al.78, 
endothelial microparticles (EMPs) from CKD patient serum as well as EMPs from senescent 
human umbilical vein endothelial cells (HUVECs) initiated VSMC calcification and osteogenic 
transformation in vitro. Prelamin A, a protein associated with Hutchinson-Gilford progeria 
syndrome, is of particular interest in this context, as aged VSMCs express significantly 
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greater quantities of this protein than young VSMCs do79. This accumulation of prelamin A is 
also associated with the presence of atherosclerosis in human arteries79, and triggers 
osteogenic differentiation of VSMCs through activation of DNA damage signalling80.  
1.2.2 Apoptosis 
Apoptosis, from ancient Greek “falling off”, describes the process of “programmed cell 
death”. It results in the removal of a particular cell, and can occur due to a number of 
reasons (summarized in Figure 1). The presence of apoptotic bodies is linked to VC, as they 
can serve as nidi for mineral nucleation, and have also been shown to initiate the process of 
calcification81-83. In addition, dialysis treatment per se can induce apoptosis in arterial tissue, 
and this increase in cell death is associated with an elevated risk of CVD84-86. 
Importantly, both senescence and apoptosis have been associated with atherosclerosis and 
endothelial dysfunction87-90. 
 
 
 
 
 
 
 
 
Figure 1. Triggers of senescence and apoptosis. Information adapted from Childs et al.91 
 
1.2.3 Estimation of biological age – telomere length 
There are several ways of assessing biological age. By far, the most common method is to 
measure telomere length and attrition rate. 
Telomeres are the structures at the ends of the DNA chromosomes (Figure 2). They consist 
of a number of TTAGGG nucleotide repeats, which form a protective cap at the end of the 
DNA molecule to prevent DNA degradation and end-point fusion of chromosomes92. Due to 
a phenomenon known as the end-replication problem, the telomeres gradually shorten with 
each cell division until the so-called Hayflick limit is reached93-95. When this occurs, the 
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telomeres signal to the cell to cease cell division through the DNA damage response (DDR)96-
98, thereby triggering cellular senescence.  
 
 
Telomere attrition rate is determined not only by cellular proliferation, but also by factors 
such as persistent inflammation99, oxidative stress100, and hyperhomocysteinemia101,  which 
are all part of the uremic phenotype. However, little is known about how drugs given during 
prolonged periods, such as immunosuppressants, affect telomere attrition.  
1.2.3.1 Folic acid, methylation and telomere length 
Folic acid, or folate, is the primary methyl donor in DNA methylation and nucleotide 
biosynthesis102-104. When folic acid levels are low, there is insufficient conversion of the 
nucleotide deoxyuridine monophosphate (dUMP) into the nucleotide deoxythymidine 
triphosphate (dTTP), resulting in increased misincorporation of dUMP into the growing DNA 
molecule during replication105. This leads to decreased DNA stability and an elevated risk of 
DNA double strand breaks105. A well-known clinical consequence of folate deficiency during 
pregnancy is spina bifida. Furthermore, low folic acid results in reduced DNA methylation, 
which in turn may affect telomere length, although findings are equivocal regarding the 
relationship between DNA methylation status and telomere length. A number of studies 
have focused on the association between telomere length and homocysteine levels, which 
are inversely correlated with folic acid106. Whereas hyperhomocysteinemia and low folic 
acid are associated with an increased risk of CVD107, as well as with decreased telomere 
length101, 108-110. DNA hypomethylation has been associated with increased telomere 
length111. Since higher folic acid has also been associated with decreased telomere length112, 
the relationships between folic acid, telomere length, and DNA methylation status are as yet 
unclear. 
Figure 2. Schematic overview of the telomere. 
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1.2.3.2 Telomere length and disease 
As many of the common chronic diseases are characterised by persistent low-grade 
inflammation, and inflammation is associated with telomere length113, a number of studies 
have investigated telomere length in patient populations with various forms of chronic 
disease. Truncated telomere length is associated with inflammatory diseases such as 
rheumatoid arthritis114, ulcerative colitis115, depression116, chronic obstructive pulmonary 
disease117, and CVD, both in the general population and in moderate CKD118, 119. In addition, 
shorter telomeres are associated with premature mortality120. 
The link between inflammation and telomere shortening suggests that interventions which 
reduce the inflammatory burden could result in reduced telomere attrition. An example of 
such an intervention is physical exercise, which has been shown to reduce inflammation121, 
122.  
1.2.4 Estimation of biological age – Cyclin-dependent kinase inhibitor 2A 
The cyclin-dependent kinase inhibitor 2A (CDKN2A) gene is located in chromosomal region 
9p21. It is a known tumour suppressor gene, and is often mutated in various forms of 
cancer123, 124. The gene encodes at least three different proteins: p16INK4a, p15INK4b and a 
protein resulting from an alternate open reading frame (ARF)125, all of which impair cell 
division and promote senescence. p16INK4a inhibits the cell cycle by binding to the cyclin-
dependent kinase 4 or 6 (CDK4/6) protein in the cytoplasm, thereby blocking its interaction 
with cyclin D126. Thus, CDK4/6 is unable to phosphorylate the retinoblastoma (Rb) protein, 
which leads to the detainment of E2F transcription factor 1 (E2F1) in the cytoplasm and the 
transition from G1 to S phase of the cell cycle is therefore unable to take place127. This 
eventually leads to irreversible cell cycle arrest, which contributes to cellular ageing. In 
Study I, we have focused primarily on the p16INK4a isoform of the CDKN2A gene.  
Through its actions as an inhibitor of the cell cycle, CDKN2A and its cognate proteins have 
been linked to increased senescence128-131. In addition, CDKN2A expression has been 
proposed to be superior to telomere length as a marker of biological age128, 129. Typically, 
p16 levels increase with age in most mammalian tissue types, including stem cells and β 
cells127. 
There are several stimuli that increase the CDKN2A, and/or the p16INK4a, expression, such as 
oncogene (RAS)-mediated senescence and the DDR through p53127. When the DNA is 
damaged, a response is activated to prevent the cell with defective DNA from dividing. As 
oxidative stress is a prominent feature in the uremic milieu, it is likely that this is a major 
inducer of p16INK4a activity in this patient group. 
  9 
1.2.4.1 CDKN2A and disease 
The 9p21 region contains several single nucleotide polymorphisms (SNPs) that consistently 
show robust associations with CVD132-134. These associations, in combination with the 
findings regarding gene expression and protein levels, indicate that there is a functional 
relationship between this locus and CVD. 
Through its effects on senescence, p16INK4a has been proposed as a causative factor in the 
detrimental effects of ageing cells on organismal health23. Using a transgenic mouse model 
to eliminate p16INK4a –positive cells accumulating with age, Baker et al.135 recently found 
that ageing-associated dysfunction in adipose and cardiac tissue was decreased. In addition, 
lifespan was extended up to 25% in mice that had undergone removal of p16INK4a –positive 
cells, with no visible effect on tumorigenesis. Interestingly, clearance of p16INK4a –positive 
cells in kidney was associated with a reduction in glomerulosclerosis135, indicating that 
senescence might not just be a consequence of CKD, but possibly also a causative agent of 
it. 
1.3 DNA METHYLATION 
The DNA molecule can undergo various chemical modifications, which regulate the usage of 
the genetic material and are vital for appropriate gene expression according to external 
stimuli and cell phenotype. Such chemical modifications include the attachment of acetyl 
and methyl groups to different parts of the molecules that make up the DNA sequence and 
the nucleosome backbone136. While acetyl groups are commonly attached to the histones of 
the nucleosome and are associated with a more open chromatin structure, a methyl group 
attached to the 5’-position of a cytosine nucleotide attached to a guanosine nucleotide is 
associated with a closed chromatin structure and reduced gene expression. Such 
methylation is termed 5’-CpG methylation, and is common throughout the genome137. 
Methylation in promoter regions is typically associated with a repressive effect on gene 
activity. Regions of 200 base-pairs containing at least 50% guanine and/or cytosine residues, 
and where the observed/statistically expected ratio of CpG dinucleotides is at least 0.6, are 
termed CpG islands (CGIs)138. CpG islands in particular are associated with gene silencing, 
and about 60% of all gene promoters in human cells contain CGIs138. Another reason for the 
focus on 5’-CpG methylation is technical feasibility; today, there are genome-wide arrays 
that allow high-throughput, rapid analysis of methylation status of as many as 850.000 
separate CpG sites, such as the Illumina Infinium HumanMethylation450 BeadChip139 that 
was used in Study III. While this array places much emphasis on CGIs, it is important to keep 
in mind that an increasing number of studies have shown that it is the methylation status of  
regions with low numbers of CpG dinucleotides that appears to be important for cell- and 
tissue-specific differentiation 140, 141.  
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It has been proposed that inflammatory status may be affected by the degree of DNA 
methylation. Altered methylation of a number of genes encoding pro-inflammatory 
molecules, such as IL-6, STAT3, and TLR genes, has been linked to the presence of chronic, 
low-grade inflammation in obesity, DM, CVD, and CKD27. Exercise, with its anti-inflammatory 
effects27, has been shown to affect the methylation status of a number of genes associated 
with inflammation and/or metabolic disease, such as TNF142, IL-10142, PGC-1α143, PPAR-δ143, 
and RUNX1144.  
1.3.1 Chronic kidney disease and DNA methylation 
Uremic toxins appear to have the potential to alter the methylation status of the genome145, 
possibly through their pro-inflammatory and oxidative stress effects. The fact that 
hyperhomocysteinemia is a prominent feature of CKD further adds to the concept of altered 
DNA methylation status in the uremic milieu. As mentioned previously, folic acid is the main 
methyl group donor in the cell, and reduced levels result in hypomethylation of the 
genome145. Despite these biologically plausible theories, only a few studies have focused on 
5’-CpG methylation in CKD.  
1.3.1.1 Global DNA methylation studies 
In a cohort of stage 3-5 CKD patients, Stenvinkel et al.146 found that inflammation was 
significantly associated with a relatively higher degree of DNA methylation as assessed by 
the luminometric methylation assay (LUMA). Patients with hypermethylated DNA had a 
worsened survival compared to those whose degree of methylation was below the median.  
Ingrosso et al.147 found that the DNA from HD patients with hyperhomocysteinemia was 
hypomethylated compared to healthy controls. However, since their finding was not 
replicated in a study comprising stage 2-4 CKD patients148, conclusions in this area are 
difficult and likely dependent on context and degree of renal dysfunction. 
1.3.1.2 Gene-specific DNA methylation studies 
Differences in DNA methylation have been associated with changes in renal function as 
assessed by estimated GFR (eGFR) in a cohort of nearly 4 000 CKD patients149. Using the 
Infinium HumanMethylation 450K BeadChip – similar to the method used in Study III in this 
thesis – the authors found several gene-specific differences in CpG methylation when 
comparing individuals with stable renal function to patients with decreasing eGFR. Genes 
displaying differences in methylation between the two patient groups include NOS3, TGFB3, 
CLU, IQSEC1, etc., and are known to be involved in pathways related to inflammation, renal 
fibrosis, oxidative stress, and epithelial to mesenchymal transition. In a study of genome-
wide methylation profiling of HD patients and age- and gender-matched healthy controls, 
Zawada et al.150 found a large number of atherosclerosis-related genes that were 
differentially methylated in the two groups. These genes had functions related to 
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inflammation, angiogenesis, cell cycle regulation, and lipid metabolism. Furthermore, 
methylation differences between diabetic patients with or without nephropathy were 
analysed by Sapienza et al.151, in an attempt to identify ESRD-specific genes while 
eliminating those with diabetes-induced methylation changes. Of the 187 genes displaying 
differences in methylation between the two groups, many had previously been associated 
with diabetic nephropathy and renal development, or had been found to be 
transcriptionally altered during dialysis treatment151. Judging by these studies, it appears 
that there are many potentially functionally relevant methylation changes in CKD patients, 
opening the door for new avenues of studies in this patient group. It is also interesting to 
note that genes involved in cellular proliferation and/or cell cycle regulation are repeatedly 
identified in these studies, further highlighting the importance of these processes in CKD. 
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2 AIMS 
The overall aim of the thesis was to examine the involvement of genetic and epigenetic 
factors in inflammation, biological age and clinical outcome in ESRD. 
Study-specific aims were as follows: 
Study I: To determine the expression of the CDKN2A gene in arterial and muscle biopsies 
from ESRD patients and to investigate correlations with age, CVD, VC, and coronary artery 
calcification (CAC) score. 
Study II: To determine longitudinal changes in telomere length in dialysis and RTx patients 
during their first 12 months of RRT, and to investigate possible associations with different 
types of immunosuppressive treatment. 
Study III: To investigate potential differences in global 5’-CpG methylation between ESRD 
patients and age- and gender-matched healthy controls, and to examine longitudinal 
changes in global methylation in dialysis and RTx patients during their first 12 months of 
RRT. 
Study IV: To investigate whether there is any association between the degree of physical 
activity and global DNA methylation in a group of Swedish senior citizens. 
Study V: To identify factors associated with an inflamed phenotype in CKD through the use 
of a mathematical model enabling simultaneous analysis of a large number of genotypes 
and phenotypes. 
Study VI: To investigate whether the CCR5Δ32 variant is associated with differences in 
mortality in ESRD patients with or without inflammation. 
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3 MATERIALS AND METHODS 
More detailed information on Materials and Methods are found in the six studies included 
in the thesis. 
3.1 COHORTS 
3.1.1 Kärl-Tx cohort 
The Kärl-Tx cohort is constituted by ESRD patients undergoing living donor (LD) RTx at the 
Karolinska University Hospital, Stockholm, Sweden. The cohort and its inclusion criteria have 
been described previously152. Briefly, whole blood, skeletal muscle, and abdominal 
subcutaneous fat (ASCF) were obtained from patients 1-2 days before LD RTx. Epigastric 
artery, ASCF, and muscle biopsies were obtained within 20 minutes after skin incision. 
Muscle samples were collected from the transverse abdominal muscle, or from the external 
or internal oblique muscle. All samples were placed in AllProtect Tissue Reagent (Qiagen) 
and stored at -70°C until RNA preparation. For immunohistochemistry (IHC), parts of the 
biopsies were fixed in 4% phosphate buffered formalin, embedded in paraffin, and cut into 
1-2 µm thick tissue sections. Medial calcification category (0-3) for each patient was 
determined by an experienced pathologist using 1-2 sections of van Kossa-stained arterial 
tissue; the degree of VC in each category has been described previously152. In addition, 
degree of VC (%) was calculated as (calcified area)/(area of tunica media and intima) using a 
Nikon Eclipse E1000 light microscope and Fiji software. The degree of VC in the different 
categories is exemplified in Figure 3.  
 
Figure 3. Degree of calcification in the Kärl-Tx cohort. 
Medial calcification score (1-3) 
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Clinical CVD was defined as the presence of cerebrovascular, cardiovascular, and/or 
peripheral vascular disease. Total CAC score was obtained by adding CAC scores in the left 
main artery, the left anterior descending artery, the left circumflex artery, and the right 
coronary artery. 
Patients from this cohort were included in Study I (n=81), II (n=47) and III (n=12).  
3.1.2 MIA cohort 
The Malnutrition, Inflammation and Atherosclerosis (MIA) cohort consists of incident 
dialysis patients at the Karolinska University Hospital, Stockholm, Sweden. More detailed 
information on inclusion criteria can be found in Stenvinkel et al17. Briefly, whole blood is 
obtained from all included subjects shortly before the initiation of dialysis treatment.  
Patients from this cohort were included in Study II (n=49), III (n=12) and V (n=225). 
3.1.3 PIVUS cohort 
The Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) cohort consists 
of individuals residing in Uppsala, Sweden, aged 70 years and above153. Written invitations 
to participate were sent out within two months of the subjects’ 70th birthdays. In total, 
1,016 individuals agreed to be included in the study, corresponding to a participation rate of 
50.1%. Subjects were carefully phenotyped for cardiovascular risk factors, and all individuals 
who provided a self-reported estimate of physical activity were included in the study 
(n=509). 
This cohort was included in Study IV (n=509). 
3.1.4 NECOSAD cohort 
The prospective Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) 
cohort consists of ESRD patients enrolled at RRT initiation from 38 Dutch dialysis centres154. 
All patients above the age of 18 years who had had no previous RRT were eligible for 
inclusion. 
A part of this cohort was included in Study VI (n=413).  
3.1.5 Control populations 
In Study II, a control population established in Glasgow was investigated. These controls 
included individuals without overt renal disease residing in Glasgow, and have been 
described in part previously155.  
In Study III, a population-based, randomly selected cohort called PRIMA controls was used. 
Participants were selected using Statistics Sweden (SCB), and the only exclusion criteria was 
unwillingness to participate. 
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3.2 STUDY I 
3.2.1 Protein and biomarker measurements 
All measurements of protein and biomarker levels were done in whole blood, plasma, or 
serum samples, and were performed at the Clinical Laboratory at Karolinska University 
Hospital, Stockholm, Sweden. Levels of IL-6, IL-8, and TNF were measured using an Immulite 
1000 Analyzer according to the manufacturer’s instructions. Pentosidine levels were 
measured using reverse-phase HPLC with gradient separation under fluorescence detection 
(excitation-emission: 335/385 nm) and 8-OHdG was measured with a commercial 
competitive enzyme-linked immunosorbent assay kit. Validated routine methods were used 
for measuring hsCRP, parathyroid hormone, plasma cholesterol, triglycerides, high-density 
lipoprotein (HDL)-cholesterol, creatinine, albumin, calcium, phosphate, and D-vitamin. 
3.2.2 RNA preparation and gene expression analysis 
Total RNA was prepared from epigastric artery and muscle using TRIzol Reagent. RNA quality 
and concentration were determined using an Agilent 2100 Bioanalyzer and a NanoDrop 
spectrophotometer, respectively. From RNA, cDNA was prepared using random hexamers 
and gene expression was determined using individual TaqMan® gene expression assays for 
target genes CDKN2A, MGP and RUNX2. A minimum of one reference gene per gene assay 
was included.  
3.2.3 Computed tomography 
A 64-channel detector was used to obtain cardiac computed tomography (CT) data. The 
amount of calcium deposition in coronary arteries was determined by a radiologist, and CAC 
was calculated using Agatston score (based on Hounsfield units)156. Total CAC score was 
calculated by adding CAC scores of the right coronary artery, the left circumflex artery, the 
left anterior descending artery, and the left main artery. Calcified plaques were considered 
to be present at > 130 Hounsfield units. 
3.2.4 Immunochemistry 
Immunohistochemical staining of p16INK4a protein was performed using an anti-
CDKN2A/p16INK4a polyclonal antibody on paraffin-embedded sections of epigastric artery. 
Diaminobenzidine (DAB) and hematoxylin were used for staining and counterstaining, 
respectively. The negative control consisted of a section without the primary antibody. 
3.2.5 Statistical analysis 
Statistical significance was set at p<0.05. All statistical analyses were performed using non-
parametric methods, since CDKN2A/p16INK4a distribution was non-normal. Hence, Wilcoxon 
rank sum test or Χ2 test was used for categorical comparisons; Spearman’s rank correlation 
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was used for determining correlation between continuous variables; and multivariate 
analysis was done using general linear model (GLM). 
3.3 STUDY II 
3.3.1 Protein and biomarker measurements 
All measurements were performed similarly to the description provided for study I (see 
section 3.2.1 for further details). 
3.3.2 Telomere length measurements 
Telomere length in whole blood was measured using the protocol developed by Cawthon, 
which is based on the quantitative PCR and Southern blot methods to determine the length 
of the telomeric region relative to a single-copy gene present in the genome157. Briefly, all 
samples were analysed in triplicate using 36B4 as a single-copy reference gene. The sample 
signal derived from the run using the telomere primers was divided by the signal obtained 
using 36B4 primers, and all samples were compared to a reference DNA sample. 
Telomere attrition (ΔT/S) was calculated as (telomere length at 12 months) – (telomere 
length at baseline). 
3.3.3 Statistical analysis 
All analyses were performed using non-parametric tests. For categorical data, Wilcoxon rank 
sum test/ Χ2 test or Fisher’s exact test was used. Spearman’s rank correlation coefficient was 
used for analysis of continuous data and Wilcoxon matched-pairs signed rank test was used 
for paired analysis of baseline and 12 month data. 
3.4 STUDY III 
3.4.1 Global DNA methylation analysis 
Global methylation status of bisulfite-treated DNA was assessed using the Illumina Infinium 
HumanMethylation450 BeadChip. Included in the study were 12 patients from the MIA 
cohort, 12 patients from the Kärl-Tx cohort and 24 healthy controls from the PRIMA cohort. 
For each patient, there was a baseline sample and a second sample obtained 12 months 
after therapy initiation. The degree of methylation was defined as the signal intensity of 
methylated alleles divided by the added intensity signals of methylated + unmethylated 
alleles. 
3.4.2 Statistical analysis 
For normalisation of data from the Illumina Infinium HumanMethylation450 BeadChip, 
quantile colour adjustment was used. Bioconductor packages lumi and limma were used for 
further data analysis. First, limma was used to find CpG sites that displayed different 
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methylation status when comparing patients to controls. Group comparisons of these sites 
were then made as follows: (1) dialysis patients versus RTx patients at baseline; (2) dialysis 
patients versus RTx patients after 12 months; (3) dialysis patients at baseline versus dialysis 
patients after 12 months; (4) RTx patients at baseline versus RTx patients after 12 months. In 
addition, CpG sites that remained differently methylated compared to controls in both 
patient groups over time were noted. Results were considered significant if the false 
discovery rate (PFDR) was less than 0.01. All probes overlapping DNA sequences containing 
SNPs were removed from analysis. 
3.4.3 Pathway analysis 
Using the output from the statistical analysis, CpG sites displaying large differences in 
methylation in any of the above-mentioned comparisons that had a gene annotation were 
entered into Ingenuity® Pathway Analysis (IPA®). 
3.5 STUDY IV 
3.5.1 Participant selection 
Subjects in the PIVUS cohort were grouped according to the degree of self-reported physical 
activity: 
Group 1 – Light physical activity < 2 times/week and no heavy physical activity (n=56); 
Group 2 – Light physical activity > 1 time/week and no heavy physical activity (n=290); 
Group 3 – Light physical activity > 1 time/week and heavy physical activity 1-2 times/week 
(n=129); 
Group 4 – Light physical activity > 1 time/week and heavy physical activity > 2 times/week 
(n=34). 
3.5.2 Measurement of global DNA methylation 
Global DNA methylation was measured using LUMA, described in detail by Karimi et al158. 
Briefly, 250-750 ng of DNA prepared from whole blood was subjected to enzymatic 
restriction treatment by either a combination of EcoRI (New England Biolabs), MspI (New 
England Biolabs), and TangoTM buffer (Fermentas), or EcoRI, HpaII (New England Biolabs), 
and TangoTM buffer. Samples were incubated for four hours at 37°C and subsequently 
analysed using Pyrosequencing®. For each sample, the MspI-specific and HpaII-specific peak 
heights were normalised using EcoRI as an internal control, and the normalised values were 
used to calculate the HpaII/MspI ratio. As HpaII is methylation-sensitive whereas MspI is 
not, a higher HpaII/MspI ratio indicates a lower level of global DNA methylation. 
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3.5.3 Statistical analysis 
For testing the association between physical activity and DNA methylation, ANOVA analysis 
was used. For studying the involvement of potential confounders (gender, fasting glucose, 
systolic and diastolic blood pressure, serum triglycerides, body mass index (BMI), low-
density lipoprotein (LDL)- and HDL-cholesterol, and smoking status), ANCOVA analysis was 
performed. 
3.6 STUDY V 
3.6.1 Patient selection 
From the MIA cohort, a set of 225 individuals with less than 5% missing data was eligible for 
analysis using the relaxed linear separability (RLS) method. Features that had been 
measured in a minimum of 65% of the patients were included in the feature set. Nearest 
neighbour imputation was used to estimate missing data. In total, 57 anthropometric or 
biochemical measurements (phenotypes) and 228 genotype features were entered into the 
model, which was asked to differentiate between inflamed and non-inflamed patients. 
Presence/absence of inflammation was defined as hsCRP above/below median (5 mg/L), 
respectively. 
3.6.2 Relaxed Linear Separability method 
The application of the RLS method in this particular dataset has been described previously 
by Bobrowski et al159. Briefly, the RLS method, combined with Convex and Piecewise – 
Linear (CPL) criterion functions was used to identify features that differ between inflamed 
and non-inflamed patients. The combination of features with the best predictive power was 
determined by the smallest apparent error (AE) and the lowest cross-validation error (CVE). 
A factor value, indicating predictive strength, was obtained for each feature included in the 
RLS model. For comparison purposes, univariate analysis (Spearman’s rank correlation 
coefficient) and principal component analysis (PCA) were performed on all features included 
in the resulting RLS model.  
3.7 STUDY VI 
3.7.1 Clinical data and definitions 
In the NECOSAD cohort, the first blood and urine samples were collected three months after 
dialysis initiation. In the MIA cohort, blood and urine samples were obtained near dialysis 
initiation. In this study, presence of inflammation was defined as an hsCRP level > 10 mg/L. 
Causes of death and primary kidney disease was categorised according to definitions from 
the European Renal Association-European Dialysis and Transplantation Association (ERA-
EDTA)160. In both cohorts, cardiovascular mortality was defined as myocardial ischemia and 
infarction, haemorrhage due to ruptured vascular aneurysm, hyperkalaemia, hypokalaemia, 
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cardiac failure/fluid overload/pulmonary oedema, cardiac arrest due to unknown cause(s), 
mesenteric infarction, cerebrovascular accident, or unknown cause of death.  
3.7.2 Genotyping of CCR5Δ32 polymorphism 
3.7.2.1 NECOSAD cohort 
In the NECOSAD cohort, genotyping of the CCR5Δ32 variant was performed using a PCR-
based allelic discrimination assay (5’ nuclease assay), as described by Clark et al38. 
3.7.2.2 MIA cohort 
In the MIA cohort, genotyping of the CCR5Δ32 variant was performed using PCR 
amplification followed by fragment size separation on 3% agarose gel with ethidium 
bromide staining. 
3.7.3 Statistical analysis 
Hardy-Weinberg equilibrium was calculated using the gene counting method. The main 
outcomes were set to all-cause and cardiovascular mortality within 5 years of follow-up. For 
categorical variables, Χ2 analysis was used, and one-way ANOVA was used for analysis of 
continuous data. Survival analysis was performed using the Kaplan-Meier method, with log-
rank test to calculate differences in survival between groups. Hazard ratios (HR) of adjusted 
(gender, BMI, age at inclusion, DM, presence of CVD, and dialysis modality) as well as 
unadjusted mortality rates were calculated using Cox’s proportional-hazard analysis. To 
examine the interaction between inflammatory status and CCR5Δ32 genotype, patients 
were divided into four groups: (1) CCR5 ins/ins, hsCRP ≤ 10 mg/L; (2) CCR5 ins/ins, hsCRP > 
10 mg/L; (3) CCR5 ins/del or del/del, hsCRP ≤ 10 mg/L; (4) CCR5 ins/del or del/del, hsCRP > 
10 mg/L. 
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4 RESULTS AND DISCUSSION 
4.1 STUDY I 
Patients suffering from CKD experience an increase in CVD morbidity and mortality 
disproportionate to their chronological age13, 15, suggesting an accelerated biological ageing 
process. In this study, gene expression of biological age marker CDKN2A/p16INK4a was 
analysed in epigastric artery and muscle obtained from ESRD patients, and possible 
differences in expression according to degree of VC, CAC score, and presence or absence of 
CVD, were investigated. Furthermore, arterial CDKN2A/p16INK4a expression was associated 
with arterial expression of MGP and RUNX2, both of which are involved in osteogenic 
transformation of VSMC61-64. 
4.1.1 Age and CDKN2A/p16INK4a expression 
When analysing the correlation of CDKN2A/p16INK4a expression with age, the association 
was significant in muscle (p=0.0003, ρ=0.33), but did not reach statistical significance in 
artery (p=0.07, ρ=0.28).  
4.1.2 Cardiovascular disease, vascular calcification and CDKN2A/p16INK4a expression  
There was no significant difference in muscle CDKN2A/p16INK4a expression according to CVD 
status. However, CDKN2A/p16INK4a expression was significantly higher in arteries from 
patients with CVD compared to those with no CVD (p=0.001) (Figure 4). 
 
 
Similarly, while there was no significant correlation between VC score and CDKN2A/p16INK4a 
expression in muscle, arterial CDKN2A/p16INK4a expression was significantly and positively 
correlated with VC score (p=0.01, ρ=0.4), and with degree of CAC by CT heart (p=0.008, 
ρ=0.46) (Figure 5A-B). 
Figure 4. Arterial CDKN2A/p16INK4a expression in ESRD 
patients with and without CVD. 
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4.1.3 Osteogenic markers and CDKN2A/p16INK4a expression 
Arterial CDKN2A/p16INK4a expression was significantly and positively correlated with both 
MGP (p=0.007, ρ=0.41) and RUNX2 (p=0.046, ρ=0.33) expression in artery. 
4.1.4 Arterial expression of p16INK4a 
Immunohistochemical analysis of arterial p16INK4a was performed in a subset of patients 
with varying degrees of VC (n=4). The protein expression appeared to mimic the gene 
expression, in that higher degrees of VC were associated with increasing p16INK4a expression. 
4.1.5 Discussion 
Study I showed significant associations between higher arterial expression of biological age 
marker CDKN2A/p16INK4a and the presence of VC and clinical CVD. This indicates a 
relationship between elevated cellular senescence and CVD. As numerous SNPs in the 
vicinity of CDKN2A have been robustly associated with CVD, the findings strengthen the 
hypothesis that there is a functional relationship between CDKN2A/p16INK4a and CVD. The 
correlation between increasing senescence, VC and CVD is consistent with current literature, 
where endothelial dysfunction and atherosclerosis has been linked to the presence of 
senescent cells83-86. 
Numerous factors present in the uremic milieu may contribute to an elevated level of 
cellular senescence – inflammation, oxidative stress and uremic toxins, to name a few. The 
persistent exposure to these factors is likely to accelerate the cellular ageing process, as 
shown in Figure 1. 
Figure 5A-B. Correlation between arterial CDKN2A/p16INK4a expression and VC (A), and between 
arterial CDKN2A/p16INK4a expression and CAC score as measured by CT heart (B). 
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The positive correlation between arterial expression of CDKN2A/p16INK4a and osteogenic 
factors MGP and RUNX2 suggests a link between cellular senescence and osteogenic 
potential in arterial tissue. While RUNX2 stimulates the osteogenic transition of VSMCs, 
MGP is a calcification inhibitor. The positive correlation between CDKN2A/p16INK4a and 
RUNX2 indicates a link between senescence and osteogenic transformation, thereby 
confirming other studies65, 76, 77. The positive correlation between MGP and 
CDKN2A/p16INK4a, while seemingly counter-intuitive, may reflect an attempt to inhibit an 
ongoing calcification process, and accords with previous findings65.  
With the exception of an association with chronological age, all significant findings were 
observed in arteries only. As skeletal muscle is considered post-mitotic161, the lack of 
associations in muscle is biologically plausible. In addition, the link to VC is functionally 
relevant in artery, but not in muscle, and as VC is a major risk factor for CVD, this may 
explain the lack of significant associations in muscle. Similarly, CAC score was positively 
associated with CDKN2A/p16INK4a expression in artery, further indicating that arterial 
CDKN2A/p16INK4a expression may be a functional biomarker for biological vascular age in 
ESRD patients. 
Some study limitations should be mentioned. The study population is a select group of 
patients with a relatively low CVD prevalence, and in some regards a healthier clinical profile 
than older, more severely ill, ESRD patients. The number of arterial RNA samples was 
reduced because of insufficient RNA quality, which was due to small biopsies. As all RNA 
samples were prepared using a homogenized tissue sample, it is impossible to conclude 
whether there were any cell-specific differences in CDKN2A/p16INK4a expression. 
Furthermore, statistical analysis of the IHC data could not be performed due to the low 
number of samples. Hence, more samples should be analysed in order to confirm the 
findings in this pilot study. In addition, it is important to remember that since VC is a locally 
occurring phenomenon in the artery, the gene expression profile and the calcification 
and/or CAC score may not correlate even though the patient is calcified.  
In summary, Study I indicates that cellular senescence is related to VC, and consequently, 
CVD in an ESRD population. In addition, the findings suggest a link between osteogenic 
potential and senescence, thus providing a partial explanation for the association between 
accelerated biological ageing and calcification.  
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4.2 STUDY II 
Patients suffering from CKD have been found to have decreased telomere length compared 
to healthy individuals119, indicating accelerated biological ageing. However, the impact of 
RRT on the degree of telomere attrition has not been studied. In addition, it is not known 
what impact immunosuppressive treatment has on telomere length. To this end, Study II 
focused on measuring whole blood telomere length longitudinally in ESRD patients 
undergoing dialysis or RTx, to compare it to telomere length in a non-CKD population, and to 
assess possible differences in telomere length between different anti-metabolite 
immunosuppressive therapies in the RTx patient population. 
4.2.1 Telomere length in patients and controls 
At baseline, both dialysis patients (median age 55 years) and RTx patients (median age 45 
years) had significantly shorter telomeres than the non-CKD controls (median age 58 years) 
(p=0.0007 and p=0.03, respectively), despite being significantly younger (p<0.0001).  
Following 12 months of RRT, the degree of telomere attrition was significantly greater in RTx 
than in dialysis patients (p=0.008). Notably, there was no significant difference in telomere 
length between the two patient populations at baseline. 
4.2.2 Telomere length and folic acid 
In RTx patients at baseline, but not in dialysis patients, telomere length was significantly 
correlated with levels of folic acid (p=0.04, ρ=-0.33) and homocysteine (p=0.04, ρ=0.29). 
4.2.3 Telomere length, folic acid and anti-metabolite therapy 
Following 12 months of RRT, RTx patients receiving the anti-metabolite mycophenolic acid 
displayed a larger degree of telomere attrition than those treated with azathioprine 
(p=0.007), whose attrition resembled that seen in dialysis patients.  
After 12 months, RTx patients receiving mycophenolic acid had higher folic acid levels than 
those treated with azathioprine (p=0.008), despite the absence of a significant difference 
between the groups at baseline (p=0.25).  
4.2.4 Discussion 
This study supports the notion that ESRD patients undergo premature ageing and are 
biologically older than non-CKD controls. Although the controls were chronologically older 
than the ESRD patients, they had longer telomeres, lending further credibility to the 
hypothesis regarding the progeric nature of ESRD.  
Our finding that RTx patients showed a larger degree of telomere attrition than dialysis 
patients following 12 months of RRT was unanticipated. This could be due to a number of 
factors. The RTx patient group was younger than the dialysis patients, and attrition rate is 
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higher in younger subjects162. Likewise, BMI has been shown to have an effect on telomere 
attrition rate163.  
Another possible explanation lies in the immunosuppressive treatment. When RTx patients 
were analysed separately according to anti-metabolite treatment, the difference in 
telomere attrition between RTx and dialysis patients was entirely due to telomere attrition 
in the mycophenolic acid-treated group. Also, the reason for the observed differences in 
folic acid levels according to type of antimetabolite treatment is unknown. However, 
previous studies show that while both mycophenolic acid and azathioprine inhibit purine 
synthesis, thereby theoretically affecting the amount of the folic acid-derivative 
tetrahydrofolate, treatment with mycophenolic acid is associated with lower homocysteine 
levels than treatment with azathioprine164. Consequently, as was observed in the current 
study, levels of folic acid should be higher in patients treated with mycophenolic acid. As 
folic acid and DNA methylation could impact telomere length, albeit in an unknown 
direction, it is likely that antimetabolite treatment caused the observed differences in folic 
acid, and telomere attrition.  
A number of caveats should be considered. The current study would benefit from a more 
well-defined control population, preferably from the same general population as the 
patients. Also, as the immunosuppressive treatment of the RTx patients was non-
randomized, it is possible that there is some unidentified clinical characteristic that 
separates the groups which has an impact on telomere length and/or folic acid. In addition, 
as it is not possible to infer any causal relationships between folic acid, telomere length, 
and/or immunosuppressive treatment, the findings in this study serve as a foundation for 
further research. Cell culture experiments would be of great interest to address the possible 
connections between medication, folic acid, and telomere attrition. 
While previous studies investigated these topics, none examined folic acid/homocysteine, 
longitudinal changes in telomere length, and immunosuppressive treatment simultaneously. 
The potential impact of commonly used immunosuppressive treatment on biological ageing 
is of particular importance in this vulnerable patient group, which is constantly exposed to 
numerous factors that may predispose to premature ageing. 
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4.3 STUDY III 
In CKD, there are several systemic factors that have the potential to impact the methylation 
status of the genome, such as inflammation, oxidative stress, and uremic toxins27, 142-145. 
While global DNA methylation has been investigated in CKD patient populations 
previously146-151, the possible impact of RRT is unknown. Study III aimed to investigate the 
changes in global DNA methylation in patients receiving dialysis treatment or undergoing 
RTx, comparing baseline samples to samples obtained after 12 months of RRT. In addition, 
age- and gender-matched healthy controls were included to illustrate normal methylation 
status, and to aid in the identification of “CKD-specific” methylation alterations. 
4.3.1 Methylation in patients versus controls 
Both patient groups were compared to the control group, before and 12 months after RRT 
initiation. In addition, CpG sites that were differently methylated compared to controls in 
both patient groups, and at both time points, were identified and those located in a gene 
were further analysed with IPA®. Results are summarized below. 
4.3.1.1 Distribution of significant CpG sites in different genomic regions 
The majority of the significant CpG sites in RTx patients were located in regions unrelated to 
genes (64.3% at baseline and 64.1% after 12 months). In dialysis patients, a higher 
percentage of the significant CpG sites were located in promoter-associated regions (42.4% 
at baseline and 51.2% after 12 months). 
In RTx patients, a majority of the significant CpG sites were not located in a CGI-related 
structure (46.3% at baseline and 47.1% after 12 months), whereas the significant CpG sites 
in dialysis patients were predominantly located in the island region (46.5% at baseline and 
59.0% after 12 months). 
Furthermore, in RTx patients, a larger proportion of the significant CpG sites were located in 
enhancers, than in dialysis patients (33% versus 18% at baseline, 33% versus 14% after 12 
months). 
4.3.1.2 CpG sites with largest methylation difference 
In RTx patients at baseline, the 10 CpG sites with the largest methylation difference 
compared to controls were located in TTC15, HLA-DRB5, PNKD, PRKAG2, FXYD2, BCL11B, 
NOSIP, IQSEC1, DGKA, and RARG. After 12 months, CpG sites in SSH3, HOXD13, EHD1, 
ACOT7, FAM24B, CDKL2, and RDH10 showed the largest fold change. In dialysis patients at 
baseline, the CpG sites with the largest methylation differences were located in the genes 
D2HGDH, CDK6, AGAP3, PNKD, HIVEP3, RNASEH2C, ZNF562, CSGALNACT2, and COL6A3. 
After 12 months of dialysis, the CpG sites with the largest fold change were located in 
D2HGDH, PNKD, EID2, AGAP3, ETS1, MRFAP1, GBX1, RNASEH2C, and ZNF224.  
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4.3.1.3 Genes with several significant CpG sites 
In dialysis patients at baseline, the genes containing the largest number of significant CpG 
sites included SKI, PRDM16, TRIM26, HDAC4, ZMIZ1, LOC146880, GFI1, HIVEP3, and 
BAHCC1, whereas after 12 months, the largest number of significant sites were found in 
MAD1L1, MYL9, LOC284837, SKI, PTPRCAP, PRDM16, MRFAP1, RPS11, FANCF, HDAC4, and 
C17orf64. In RTx patients at baseline, the genes with the highest number of significant sites 
included MAD1L1, HDAC4, RPTOR, TBCD, NCOR2, RASA3, KCNQ1, ANKRD11, and BCL11B. 
After 12 months, RASA3, MAD1L1, TBCD, RPTOR, DDR1, BANP, ARID3A, FOXK1, ITPKB, and 
HDAC4 had the highest number of significant CpG sites. 
4.3.1.4 CpG sites with persistent differences in methylation 
In total, 413 genes containing at least one significant CpG site remained differently 
methylated in both patient groups compared to controls over 12 months of RRT.  
4.3.1.5 Ingenuity Pathway Analysis® 
To investigate whether methylation differences between patients and controls were located 
in genes related to any particular biological function, all differently methylated CpG sites 
with a gene affiliation were entered into IPA®. This was done for both patient groups at both 
time points, as well as for those CpG sites that remained differently methylated compared 
to controls in both patient groups. Several of the canonical pathways were related to cell 
growth and/or cell proliferation, cell cycle regulation, cancer, and immune response. 
4.3.2 Discussion 
Until now, potential changes in global methylation during RRT have been unexplored. Our 
results showed that over 12 months of dialysis, or 12 months after RTx, significant 
differences in DNA methylation between ESRD patients and age- and gender-matched 
healthy controls were reduced. This could be a reflection of the observed normalisation of 
the toxic uremic milieu that occurs both in dialysis and RTx patients.  
Many of the differently methylated CpG sites were located in genes with functions related 
to apoptosis, cell cycle regulation, and cell survival, such as ANKRD11165, ARID3A166, 167, 
BANP168, BCL11B169, EID2170, ETS1171, GFI1172, HIVEP3173, MAD1L1174, MRFAP1175, NCOR2176, 
177, SKI178, 179, ZMIZ1180, and ZNF224181. This is especially interesting given the association 
between cellular senescence and CKD-related comorbidities such as CVD. It also points to a 
potentially altered rate of biological ageing in CKD patients. 
In addition to the link with cell cycle regulation and cellular senescence, several of the 
differently methylated CpG sites were located in genes associated with kidney disease, or 
with prominent CKD comorbidities such as CVD, DM and inflammation. Examples of these 
include BCL11B182, COL6A3183, 184, DDR1185, 186, DGKA187, HDAC4188, KCNQ1189, 190, NCOR2191,  
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PRDM16192, 193, PRKAG2194, 195, and RPTOR196. Inflammation may be the common 
denominator in this context, as it is associated with both CVD, DM197, and CKD20, and 
accelerates cellular ageing16, 19. 
While treatment effects on methylation of specific CpG sites are intriguing, the gene 
affiliation of the CpG sites whose methylation status remained unchanged when comparing 
patients and controls at either time point, is of equal interest. It is tempting to speculate 
that this set of genes is specific for CKD, as their methylation status was unaltered despite a 
normalisation of renal function. Interestingly, pathway analysis of this group of genes 
revealed a connection to biological ageing, and ageing-associated processes, such as 
oxidative stress and insulin/insulin growth factor signalling. IGF-1 signalling has been 
robustly associated with biological ageing198, and it also induces STAT3 signalling199. 
Meanwhile, Rac signalling is related to STAT3200, and is associated with various cardiac 
diseases and renal podocyte damage201. Loss of the PTEN tumour suppressor gene induces 
cellular senescence202. In addition, the PTEN promoter methylation status has been 
associated with the metabolic syndrome203, and PTEN protein levels have been associated 
with muscle wasting, a common feature of CKD204. 
The differences in distribution of differently methylated CpG sites between the two patient 
populations were surprisingly consistent over 12 months of RRT. While the underlying 
reason(s) for this are unknown, it is possible that it reflects differences between the two 
groups. Indeed, ESRD patients who are not on the RTx waiting list and remain on dialysis 
have been found to have worse general health and long-term survival compared to patients 
who are on the waiting list205. In our dataset, patient characteristics between the groups 
were rather similar overall. However, dialysis patients had higher levels of IL-6, both at 
baseline and after 12 months, indicating an elevated degree of inflammation compared to 
patients selected for LD RTx. IL-6 is a prominent member of the SASP206, which has been 
hypothesized to aggravate, or even cause, age-related diseases207. Finally, the differences in 
methylation status could be due to differences in medication. RTx patients started 
immunosuppressive regimen 1-2 days before the baseline sample. Since the effects of 
steroid treatment on global methylation status are largely unknown27, this possibility clearly 
motivates further study. 
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4.4 STUDY IV 
Global methylation status has been associated with inflammation208, CVD209, CKD, and 
ESRD146. Inflammation can be reduced with physical activity48, 52, and there have been 
studies demonstrating a connection between methylation status of individual genes and 
amount of exercise210-212. This study aimed to investigate the relationship between self-
reported physical activity and global DNA methylation in a cohort of senior citizens (aged ≥ 
70 years) residing in Uppsala, Sweden. 
4.4.1 Physical activity and DNA methylation 
Individuals with a higher amount of self-reported physical activity had a significantly lower 
degree of global DNA methylation (ANOVA p=0.01).  
After adjusting for cardiovascular risk factors (gender, BMI, systolic and diastolic blood 
pressure, serum triglycerides, LDL- and HDL-cholesterol, fasting glucose, and smoking 
status), the association remained significant (ANCOVA p < 0.05). 
4.4.2 Discussion 
The results of this study demonstrate that more physical activity is associated with a lower 
level of DNA methylation, a finding which remained significant after adjusting for numerous 
potential confounding factors that are risk factors for CVD. As physical activity reduces the 
presence of inflammation48, 52, it could be hypothesised that lower circulating amounts of 
pro-inflammatory cytokines and other inflammatory factors contribute to alterations in the 
methylation status of the DNA molecule. This accords with previous findings in CKD patients, 
where a higher degree of inflammation was associated with increased global DNA 
methylation146. However, as information regarding individual inflammatory status was 
lacking in this study, it is not possible to show whether DNA methylation and degree of 
inflammation were correlated in this particular cohort. The results could reflect a worsened 
overall health status in individuals with low versus high physical activity.  
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4.5 STUDY V 
Being a complex disease, CKD is characterized by the presence of multiple underlying 
factors, which interact to form the uremic phenotype. Studying all of these factors 
separately is not only expensive and time-consuming, but also greatly increases the risk of 
false-positive associations as the number of tests performed rapidly accumulates. We 
explored the possibility to obtain a more comprehensive assessment by simultaneously 
entering a large number of genetic and/or anthropometric data points into an advanced 
mathematical model in order to identify features predictive of a specific outcome. 
Study V was performed as a follow-up study of a previous study from our group, where the 
RLS method was used to identify features predictive of presence/absence of inflammation in 
a cohort of 225 incident dialysis patients159. In the present study, we describe the results in 
more detail. 
4.5.1 Factor summary 
In the foregoing study159 we showed that it was possible to separate inflamed from non-
inflamed CKD patients (defined as a CRP level above or below 5 mg/L, respectively) using the 
RLS method. In the current study, a total of 57 anthropometric or biochemical data points 
and 228 genotype features were entered into the model. Of these, the smallest AE (0%) and 
CVE (1.8%) was obtained when 60 features were included in the analysis. Thirty-one of 
these 60 features were genetic, whereas the remaining 29 were anthropometric or 
biochemical.  
All 60 features were also included in a PCA as well as univariate analysis using Spearman’s 
rank correlation coefficient. The results showed that there was no single component that 
could explain a great degree of the variance in the dataset (maximum 7%), and a 
combination of the ten features with the highest factor values could explain only 40% of the 
variance. In addition, the univariate analysis identified 17 statistically significant features 
(p<0.05) as opposed to the 60 features included in the RLS model, demonstrating that the 
RLS model provides added value to the conventional approach. 
4.5.2 Strongest factors 
The ten features with the highest predictive factor values included eight genetic features 
and two anthropometric or biochemical features. Specifically, these were polymorphisms in 
the NAMPT, CIITA, CEP89, BMP2, NOS3, and PIK3CB genes, and levels of fibrinogen and 
bone mineral density (BMD). 
4.5.3 Discussion 
We found many advantages using a mathematical method that enables simultaneous study 
of a large number of features. First, the number of statistical tests performed are reduced, 
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thereby minimising the risk of false-positive findings. Second, it represents a biologically 
relevant way of observing mechanisms and processes, as each feature entered in the model 
is considered in context with other features and not in isolation. Third, it is a less biased way 
of analysing the dataset, as the inclusion of all available information in the model precludes 
preconceptions of which feature(s) should be studied. That being said, it is important to 
remember that the original collection of data is obviously subject to bias. 
The usefulness of this type of analysis becomes evident when subjecting the same dataset 
to PCA and univariate analysis. Not unexpectedly, PCA failed to identify any principal 
component explaining a substantial part of the variance; even when including 10 features, 
the variance explained only amounted to 40%. For complex diseases, such as CKD, PCA is 
not an entirely suitable tool. Likewise, univariate analysis is inappropriate in complex 
disease, albeit for different reasons. Statistically, it is unsound to perform a large number of 
separate tests as it greatly increases the risk of false-positive results, while correction for 
multiple testing can be too stringent and result in false-negative findings. The 17 features 
that reached statistical significance following univariate analysis were all consistent with the 
RLS factor values, i.e., a feature identified as having a positive effect on the presence of 
inflammation in the RLS model also had a positive ρ-value in the univariate analysis. 
Many of the 60 features included in the RLS model are known to be associated with 
inflammation. These include, but are not limited to, the rs3091244 SNP in the CRP gene, as 
well as and fibrinogen and IL-6 levels. This shows that the RLS model is able to identify 
validated inflammatory markers, thereby adding further credibility to its usefulness in 
complex datasets such as this. 
Features that were not found to be predictive of inflammatory status are also of interest. 
Both DM and CVD, two conditions commonly associated with systemic inflammation, failed 
to add predictive value to the RLS model. This indicates that in CKD patients, features other 
than these two common comorbidities are more powerful determinants of the presence or 
absence of inflammation in the uremic milieu. 
Some caveats of the study should be considered. It is important to note that no information 
regarding causality can be derived from the RLS analysis. In addition, the features included 
in the model cannot be studied separately, as the factor strengths and relative relationships 
between the features are only valid in this particular combination and setting. Finally, the 
results presented in this study should be replicated in a separate cohort, with similar genetic 
and anthropometric/biochemical data available. 
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4.6 STUDY VI 
The presence of a persistent, low-grade inflammation that is commonly seen in CKD and 
ESRD patients has been hypothesised to exacerbate CVD and many of the comorbidities 
observed in the uremic milieu20, 28, 29. 
This study sought to investigate the relationship between presence of inflammation, 
CCR5Δ32 genotype, and outcome in two separate populations of incident dialysis patients. 
4.6.1 Genotype frequency 
In the NECOSAD cohort (n=413), the CCR5 deletion allele was present at a frequency of 
19.4% (ins/del heterozygote and del/del homozygote individuals), whereas the frequency in 
the MIA cohort (n=302) was 18.6%. Genotype distributions were in Hardy-Weinberg 
equilibrium in both populations (NECOSAD p=0.21, MIA p=0.22), and were not significantly 
different (p=0.96). In the NECOSAD cohort, patients with the deletion allele more frequently 
used anti-hypertensive medication (p=0.01). 
4.6.2 Mortality rates according to inflammatory status and CCR5Δ32 genotype 
In the NECOSAD cohort, there was no significant difference in CRP levels between patients 
with and without the CCR5 deletion allele (p=0.22). Inflamed patients had a higher mortality 
rate than non-inflamed patients (log rank: p<0.01). This was true for cardiovascular, non-
cardiovascular, as well as for all-cause death, and was confirmed by Cox regression analysis. 
When further dividing the patients according to presence/absence of the CCR5 deletion 
allele, individuals with hsCRP > 10 mg/L carrying the ins/ins genotype had the highest 
mortality rate. Inflamed patients with the deletion allele had a reduced mortality hazard 
ratio, especially for cardiovascular mortality. CRP levels were associated with cardiovascular 
mortality in ins/ins homozygotes, but not in patients carrying the deletion allele  
Results in the MIA cohort confirmed the findings in the NECOSAD cohort. However, while 
differences in cardiovascular mortality were significant, there was no significant difference 
in non-cardiovascular mortality between the four different groups when patients were 
divided according to inflammation and genotype status. 
When combining the two cohorts, confidence intervals (CI) were improved, and the overall 
results remained the same as those initially seen in the NECOSAD cohort. 
4.6.3 Discussion 
This study highlights the interplay between a clinical biomarker (inflammation) and 
genotype (CCR5Δ32) on mortality, and is an example of interactions between genotype and 
environment. The fact that the results were similar in two independent patient populations 
strengthens the study. 
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Considering that the CCR5 protein is involved in recruiting inflammatory cells to the 
endothelium35, and that the CCR5Δ32 variant has been associated with atherosclerosis43-47, 
it is not surprising that the differences in mortality were particularly pronounced for 
cardiovascular mortality in both patient cohorts.  
Some shortcomings of the study are worth noting. First, mechanistic studies are needed 
before any conclusions can be made regarding a functional association between the 
CCR5Δ32 variant, inflammation, and mortality. Second, the CRP level used to define 
inflammation status was based on a single measurement. An attempt was made to partly 
counteract this by excluding samples with an hsCRP of 50 mg/L or more. The hsCRP cutoff of 
10 mg/L can also be discussed. Still, this is a commonly used cutoff level, and replacing it 
with the median hsCRP level as a cutoff yielded the same results. 
As presence of the CCR5 deletion allele appears to attenuate the effects of inflammation on 
mortality, especially with regards to cardiovascular mortality, it is tempting to speculate 
about the potential effects of a CCR5 antagonist. Since animal studies have indicated that 
such a drug could have beneficial effects on organ rejection213, it could be of interest for 
clinical use in ESRD. The only such drug currently approved for use in humans is maraviroc, 
and it only has Food and Drug Administration (FDA) approval for HIV-1-infected individuals 
with R5-tropic virus214. DeJesus et al.215 found that HIV-1 patients who received maraviroc 
had better lipid profiles and a reduced need of lipid-lowering treatment compared to 
patients who received the standard drug regimen of combivir + efavirenz, supporting the 
idea of a potential benefit of a CCR5 antagonist in populations at high risk of CVD. As animal 
studies have also demonstrated benefits of blocking CCR5 with regards to atherosclerosis 
and CVD45, 47, 216, 217, performing studies of CVD prevalence in HIV-1 patient populations 
with/without maraviroc treatment should be of great interest.  
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5 SUMMARY AND CONCLUDING REMARKS 
The research field of cellular senescence, CKD, CVD, and inflammation is highly dynamic and 
rapidly evolving. The findings discussed in the manuscripts and introduction of this thesis 
may be applicable not only to CKD and/or ESRD patients, but also to other disorders 
characterized by inflammation, premature ageing, and CVD, such as rheumatoid arthritis, 
DM, and systemic lupus erythematosus.  
Cardiovascular disease is a prominent feature of several public health priorities, ranging 
from metabolic diseases to autoimmune disorders and psychiatric illnesses. While these 
diseases may differ with regard to causative factors, they all share an inflammatory 
component, which in turn results in exaggerated oxidative stress, increased cellular 
proliferation and DNA stress. These factors induce cellular senescence, which has 
detrimental effects on vascular tissue in addition to the harmful consequences of the 
systemic inflammation per se. In vasculature, inflammation and senescence promote VC and 
arterial stiffness, two established risk factors for CVD. Hence, the common denominator 
between chronic debilitating diseases with an over-representation of CVD might be 
inflammatory-driven accelerated biological ageing (so-called “inflammaging”). Study I in this 
thesis demonstrates a link between the tumour suppressor gene (and known inducer of 
senescence) CDKN2A/p16INK4a and VC/CAC score in arteries from ESRD patients undergoing 
LD RTx. This relationship is further related to osteogenic transformation, as the expression 
of CDKN2A/p16INK4a was positively correlated with MGP as well as with RUNX2. The concept 
of advanced cellular ageing in ESRD is further discussed in Study III, where a genome-wide 
analysis of DNA methylation revealed significant differences in methylation between 
patients and controls in genes related to cellular proliferation and/or cell cycle regulation, as 
well as in genes previously associated with CVD, CKD, and/or DM. Biological age is also the 
focus of investigation in Study II, as longitudinal changes in telomere length were measured 
in ESRD patients during their first year of RRT (either dialysis or LD RTx). Unexpectedly, we 
found that higher telomere attrition was linked to RTx as opposed to dialysis treatment. 
Folate and immunosuppressive therapy are tentatively related to telomere length, 
highlighting the ageing potential of immunosuppressants. In addition, since ESRD patients, 
while significantly younger, had shorter telomeres than the non-CKD controls, this 
observation further adds to the concept of CKD as a progeric state. 
Inflammation is a common feature of CKD and many disorders associated with premature 
ageing, and is linked to an accelerated cellular ageing. In addition, inflammation has been 
proposed to be associated with alterations in the epigenome, a hypothesis supported by 
Study IV. Here, elderly individuals engaging in regular physical activity – known to have anti-
inflammatory effects – had relatively less methylated DNA than individuals who did not 
exercise. The complex nature of inflammation and mortality is exemplified in Study VI, 
where the effects of inflammatory status on outcome – particularly with regard to 
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cardiovascular mortality – is modified by the presence of a particular genetic variant in the 
CCR5 gene. The importance of the genetic background for inflammation is highlighted in 
Study V, in which we report that 31 of 60 predictive features of inflammation were genetic. 
Together with existing literature, the studies in this thesis support the importance of 
biological ageing and inflammation in CVD and CKD, and provide novel ideas for research 
avenues for the future. 
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6 FUTURE PERSPECTIVES 
The studies performed in this thesis form a basis for several possible future investigations. 
Expanding the p16INK4a IHC experiments from Study I is highly pertinent, as the sample size 
in the study was too small to be analysed statistically. In addition, it would be interesting to 
perform basic mechanistic studies on the interplay between CDKN2A/p16INK4a, MGP, RUNX2 
and calcification – preferably in vitro, and possibly while adding uremic serum to the cell 
culture. Although Study II suggests an intriguing association between immunosuppressive 
therapy and biological ageing in RTx patients, much remains to be explored until our 
observations can have clinical implications. In vitro studies and replication in an independent 
larger cohort are necessary, and the inclusion of other markers of biological age would also 
be beneficial. Further investigation of the epigenome in CKD is also warranted, with in-
depth confirmation of methylation status and effects on gene and protein expression. As 5-
CpG methylation is only one of many possible epigenetic alterations, much remains to be 
done – in CKD and other diseases – in the areas of histone modification and microRNA 
effects. Future research should take into consideration the interplay between 
environmental exposure and genetic background, a complex relationship which requires 
time and solid statistical expertise to address. Finally, all of the studies included in this thesis 
– and indeed much of the research being conducted – would benefit from a design where 
the hypothesis is followed all the way from DNA to protein effects. While time-consuming, 
this is the only way to ensure that observations made at a genetic level are functionally 
relevant – and to what extent protein effects are caused by genetic, as opposed to 
environmental, factors. 
While it is difficult to make any prophecies regarding therapeutic potential in this field at 
such an early stage, there are several venues that deserve deeper investigation. The 
prospects of using a CCR5 antagonist have already been mentioned, and exploring the 
effects of the commercially available drug maraviroc on CVD should be an attainable goal. In 
addition, the field of senolytic drugs is a novel and fascinating area of study. Specific 
clearance of senescent cells can be achieved by different drugs already in use for other 
clinical indications. As senescent cells have been likened to cancer cells, in that both cell 
types successfully avoid entering apoptosis73, drugs normally used for cancer treatment 
have been shown to successfully and specifically eradicate senescent cells73. Animal models 
have shown promise in this field, as the elimination of senescent cells in Ercc1-/Δ mice 
improved cardiac function and exercise capacity, delayed symptoms and disease related to 
ageing, and resulted in an extended lifespan73. Clearly, this is a promising avenue of research 
and would greatly benefit from more investigation. As each senolytic drug appears to be 
rather cell type-specific73, screening tests need to be undertaken so as to identify suitable 
drug candidates for different tissues. 
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Overall, the field of cellular senescence in ageing-associated disorders would greatly benefit 
from a translational approach by researchers specialized in different fields coming together 
and exchanging ideas, as there are likely more things in common than there are separating 
factors. It is time to start viewing chronic, debilitating inflammatory diseases in a different 
light – not as separate organ-specific entities, but as varying clinical manifestations of a 
shared molecular pathogenesis provoked by persistent inflammation. 
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